These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

170 related articles for article (PubMed ID: 38140082)

  • 1. Body Surface Area-Based Dosing of Mycophenolate Mofetil in Pediatric Hematopoietic Stem Cell Transplant Recipients: A Prospective Population Pharmacokinetic Study.
    Park HJ; Hong KT; Han N; Kim IW; Oh JM; Kang HJ
    Pharmaceutics; 2023 Dec; 15(12):. PubMed ID: 38140082
    [TBL] [Abstract][Full Text] [Related]  

  • 2. An age-dependent pharmacokinetic study of intravenous and oral mycophenolate mofetil in combination with tacrolimus for GVHD prophylaxis in pediatric allogeneic stem cell transplantation recipients.
    Bhatia M; Militano O; Jin Z; Figurski M; Shaw L; Moore V; Morris E; Tallamy B; van deVen C; Ayello J; Baxter-Lowe L; Satwani P; George D; Bradley MB; Garvin J; Cairo MS
    Biol Blood Marrow Transplant; 2010 Mar; 16(3):333-43. PubMed ID: 19835971
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacokinetics of mycophenolic acid after haplo-hematopoietic stem cell transplantation in Japanese recipients.
    Uchiyama K; Saito Y; Takekuma Y; Sugita J; Teshima T; Sugawara M
    J Oncol Pharm Pract; 2022 Jan; 28(1):31-38. PubMed ID: 33349149
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A Pilot Study of Continuous Infusion of Mycophenolate Mofetil for Prophylaxis of Graft-versus-Host-Disease in Pediatric Patients.
    Windreich RM; Goyal RK; Joshi R; Kenkre TS; Howrie D; Venkataramanan R
    Biol Blood Marrow Transplant; 2016 Apr; 22(4):682-689. PubMed ID: 26740371
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Mycophenolate mofetil administered every 8 hours in combination with tacrolimus is efficacious in the prophylaxis of acute graft versus host disease in childhood, adolescent, and young adult allogeneic stem cell transplantation recipients.
    Militano O; Ozkaynak MF; Mehta B; van deVen C; Hamby C; Cairo MS
    Pediatr Blood Cancer; 2018 Aug; 65(8):e27091. PubMed ID: 29667720
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Area-under-the-Curve-Based Mycophenolate Mofetil Dosage May Contribute to Decrease the Incidence of Graft-versus-Host Disease after Allogeneic Hematopoietic Cell Transplantation in Pediatric Patients.
    Carlone G; Simeone R; Baraldo M; Maestro A; Zanon D; Barbi E; Maximova N
    J Clin Med; 2021 Jan; 10(3):. PubMed ID: 33494356
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacokinetics of mycophenolate mofetil in stable pediatric liver transplant recipients receiving mycophenolate mofetil and cyclosporine.
    Lobritto SJ; Rosenthal P; Bouw R; Leung M; Snell P; Mamelok RD
    Liver Transpl; 2007 Nov; 13(11):1570-5. PubMed ID: 17969194
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Population pharmacokinetics of mycophenolate mofetil in pediatric patients early after liver transplantation.
    Wei Y; Wu D; Chen Y; Dong C; Qi J; Wu Y; Cai R; Zhou S; Li C; Niu L; Wu T; Xiao Y; Liu T
    Front Pharmacol; 2022; 13():1002628. PubMed ID: 36313303
    [No Abstract]   [Full Text] [Related]  

  • 9. Population pharmacokinetics and dosing regimen optimization of tacrolimus in Chinese pediatric hematopoietic stem cell transplantation patients.
    Wang D; Chen X; Xu H; Li Z
    Xenobiotica; 2020 Feb; 50(2):178-185. PubMed ID: 30938547
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Intensified Mycophenolate Mofetil Dosing and Higher Mycophenolic Acid Trough Levels Reduce Severe Acute Graft-versus-Host Disease after Double-Unit Cord Blood Transplantation.
    Harnicar S; Ponce DM; Hilden P; Zheng J; Devlin SM; Lubin M; Pozotrigo M; Mathew S; Adel N; Kernan NA; O'Reilly R; Prockop S; Scaradavou A; Hanash A; Jenq R; van den Brink M; Giralt S; Perales MA; Young JW; Barker JN
    Biol Blood Marrow Transplant; 2015 May; 21(5):920-5. PubMed ID: 25687796
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Optimization of the dosing regimen of mycophenolate mofetil in pediatric liver transplant recipients.
    Barau C; Barrail-Tran A; Hemerziu B; Habes D; Taburet AM; Debray D; Furlan V
    Liver Transpl; 2011 Oct; 17(10):1152-8. PubMed ID: 21695772
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacokinetics of mycophenolate mofetil in hematopoietic stem cell transplant recipients.
    van Hest RM; Doorduijn JK; de Winter BC; Cornelissen JJ; Vulto AG; Oellerich M; Löwenberg B; Mathot RA; Armstrong VW; van Gelder T
    Ther Drug Monit; 2007 Jun; 29(3):353-60. PubMed ID: 17529894
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A Limited Sampling Strategy for Therapeutic Drug Monitoring of Mycophenolate Mofetil for Prophylaxis of Acute Graft-Versus-Host Disease in Allogeneic Stem Cell Transplantation.
    Gota V; Purohit V; Gurjar M; Nayak L; Punatar S; Gokarn A; Bonda A; Bagal B; Vora CS; Patil A; Nookala M; Khattry N
    Cell Transplant; 2020; 29():963689720912925. PubMed ID: 32495641
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Addition of sirolimus to standard cyclosporine plus mycophenolate mofetil-based graft-versus-host disease prophylaxis for patients after unrelated non-myeloablative haemopoietic stem cell transplantation: a multicentre, randomised, phase 3 trial.
    Sandmaier BM; Kornblit B; Storer BE; Olesen G; Maris MB; Langston AA; Gutman JA; Petersen SL; Chauncey TR; Bethge WA; Pulsipher MA; Woolfrey AE; Mielcarek M; Martin PJ; Appelbaum FR; Flowers MED; Maloney DG; Storb R
    Lancet Haematol; 2019 Aug; 6(8):e409-e418. PubMed ID: 31248843
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A pilot study of tacrolimus and mycophenolate mofetil graft-versus-host disease prophylaxis in childhood and adolescent allogeneic stem cell transplant recipients.
    Osunkwo I; Bessmertny O; Harrison L; Cheung YK; Van de Ven C; del Toro G; Garvin J; George D; Bradley MB; Wolownik K; Wischhover C; Levy J; Skerrett D; Cairo MS
    Biol Blood Marrow Transplant; 2004 Apr; 10(4):246-58. PubMed ID: 15077223
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacokinetics of oral mycophenolate mofetil in combination with CsA in dogs after nonmyeloablative allogeneic hematopoietic stem cell transplantation.
    Lange S; Mueller SC; Altmann S; Dahlhaus M; Drewelow B; Freund M; Junghanss C
    Bone Marrow Transplant; 2008 Apr; 41(7):667-74. PubMed ID: 18084333
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacokinetics-based optimal dose-exploration of mycophenolate mofetil in allogeneic hematopoietic stem cell transplantation.
    Okamura A; Yamamori M; Shimoyama M; Kawano Y; Kawano H; Kawamori Y; Nishikawa S; Minagawa K; Yakushijin K; Katayama Y; Sakaeda T; Hirai M; Matsui T
    Int J Hematol; 2008 Jul; 88(1):104-110. PubMed ID: 18473127
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Limited sampling models and Bayesian estimation for mycophenolic acid area under the curve prediction in stable renal transplant patients co-medicated with ciclosporin or sirolimus.
    Musuamba FT; Rousseau A; Bosmans JL; Senessael JJ; Cumps J; Marquet P; Wallemacq P; Verbeeck RK
    Clin Pharmacokinet; 2009; 48(11):745-58. PubMed ID: 19817503
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical Pharmacokinetics of Mycophenolic Acid in Hematopoietic Stem Cell Transplantation Recipients.
    Zhang D; Chow DS
    Eur J Drug Metab Pharmacokinet; 2017 Apr; 42(2):183-189. PubMed ID: 27677732
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Mycophenolate, clinical pharmacokinetics, formulations, and methods for assessing drug exposure.
    Tett SE; Saint-Marcoux F; Staatz CE; Brunet M; Vinks AA; Miura M; Marquet P; Kuypers DR; van Gelder T; Cattaneo D
    Transplant Rev (Orlando); 2011 Apr; 25(2):47-57. PubMed ID: 21190834
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.